<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03244189</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00083271</org_study_id>
    <secondary_id>1U01DK110988</secondary_id>
    <nct_id>NCT03244189</nct_id>
  </id_info>
  <brief_title>Prevention of Urinary Stones With Hydration</brief_title>
  <acronym>PUSH</acronym>
  <official_title>Prevention of Urinary Stones With Hydration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized clinical trial to investigate the impact of increased fluid intake and increased&#xD;
      urine output on the recurrence rate of urinary stone disease (USD) in adults and children.&#xD;
      The primary aim of the trial is to determine whether a multi-component program of behavioral&#xD;
      interventions to increase fluid intake will result in reduced risk of stone disease&#xD;
      progression over a 2-year period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two arm randomized controlled trial that incorporates pragmatic features, an&#xD;
      adaptable intervention, patient choice, and remote monitoring of fluid intake through a&#xD;
      &quot;smart&quot; water bottle. The study period is 24 months and will enroll approximately 1642&#xD;
      participants. Randomization will be stratified within a study site by age (adult vs.&#xD;
      adolescent) and first time vs. recurrent stone former.&#xD;
&#xD;
      Intervention and control arm study participants will receive a smart water bottle that&#xD;
      records daily fluid consumption, usual care including guideline-based recommendations of&#xD;
      adequate fluid intake to decrease kidney stone recurrence, and periodic 24 hour urine&#xD;
      collections, imaging (low-dose CT scan or ultrasound) and follow-up questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>The Principal Investigator and site investigators, along with the primary study statistician will remind blinded throughout the trial.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Stone passage observed and/or captured by the study participant.</measure>
    <time_frame>From Baseline through 24 months.</time_frame>
    <description>Will be measured by the time from Baseline to the passage of 1 or more stones by a participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural intervention for symptomatic stone</measure>
    <time_frame>From Baseline through 24 months.</time_frame>
    <description>From Baseline through 24 months; will be measured by the time from Baseline to a procedure to remove a symptomatic stone by a participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Any procedural intervention for removal of asymptomatic renal or ureteral stone</measure>
    <time_frame>From Baseline through 24 months.</time_frame>
    <description>Will be measured by the time from Baseline to a procedure to remove an asymptomatic stone by a participant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asymptomatic formation of new stone detected by imaging</measure>
    <time_frame>From Baseline through 24 months.</time_frame>
    <description>Will be measured by the time from Baseline to the formation of an asymptomatic stone by a participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in size of existing stone by ≥ 2 mm in any dimension detected by imaging</measure>
    <time_frame>From Baseline through 24 months.</time_frame>
    <description>Comparison of the size of any stone on first observation versus later observations or at passage. Will be measured primarily through imaging (CT scan or ultrasound).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite outcome: symptomatic stone recurrence, asymptomatic stone formation, increase of existing stone by ≥2 mm in any dimension detected by imaging</measure>
    <time_frame>From Baseline through 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urine total volume</measure>
    <time_frame>From Baseline through 24 months.</time_frame>
    <description>Will measure and compare 24 hour urine volumes from screening through 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs of study interventions and treatments for USD during the follow-up period</measure>
    <time_frame>Compared total between Baseline and the Month 24 visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of lower urinary tract symptoms (Comprehensive Assessment of Self-reported Urinary Symptoms)</measure>
    <time_frame>From Baseline through the Month 24 visit.</time_frame>
    <description>Will compare the results of the CASUS questionnaires completed throughout the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1642</enrollment>
  <condition>Urinary Stones</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the intervention arm will receive an individualized &quot;fluid prescription&quot;, which will be the additional volume of fluid intake needed to maintain a study-specified urine output. This fluid will be consumed from and measured by a smart water bottle. The intervention arm also includes a behavioral program that consists of financial incentives and structured problem solving (SPS) to maintain the recommended fluid intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in the control arm will receive standard care instructions according to American Urological Association (AUA) guidelines to increase overall fluid consumption to achieve study-specified urine output. They will also receive a &quot;smart&quot; water bottle with capability to self-monitor their fluid intake.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Fluid prescription</intervention_name>
    <description>The additional amount of fluid that the participant will need to consume each day, using the smart water bottle, in order to meet the study-specified urine output. This fluid is in addition to any other sources of fluid (ex. cups of coffee, bottled sports drink) that the participant consumes each day.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Financial incentive</intervention_name>
    <description>Participants in the Intervention Arm who meet their fluid intake goal on randomly selected days will receive a small payment for that day.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Structured Problem Solving</intervention_name>
    <description>Structure Problem Solving involves interactions with health coaches to help participants develop feasible solutions to overcoming personal barriers to maintaining the prescribed fluid intake.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥ 12 years&#xD;
&#xD;
          2. At least 1 symptomatic stone event (passage or procedural intervention) within 3 years&#xD;
             prior to enrollment or a symptomatic stone event within 5 years if the patient also&#xD;
             has new stone formation detected on imaging during the last 5 years. Symptomatic stone&#xD;
             defined as any of the following:&#xD;
&#xD;
               1. Stone passage&#xD;
&#xD;
               2. Procedural intervention&#xD;
&#xD;
               3. Radiographically or ultrasonographically confirmed stone with any of the&#xD;
                  following:&#xD;
&#xD;
             i. Gross hematuria ii. Renal colic or atypical abdominal pain attributed to the stone,&#xD;
             as determined by a treating provider iii. A clinical pattern of intermittent symptoms&#xD;
             consistent with intermittent obstruction at the ureteropelvic junction, as determined&#xD;
             by a treating provider&#xD;
&#xD;
          3. Low 24-hr urine volume&#xD;
&#xD;
               1. ≥18 years old: &lt;2.0 L/day&#xD;
&#xD;
               2. &lt;18 years old: &lt;25 ml/Kg/day up to 2.0L/day&#xD;
&#xD;
          4. Able to provide informed consent (parental permission for children)&#xD;
&#xD;
          5. Owning and willing to use a smartphone or other device (e.g., tablet) compatible with&#xD;
             the study-provided wireless enabled &quot;smart&quot; bottle&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Spinal cord injury&#xD;
&#xD;
          2. Currently undergoing active treatment for cancer except basal cell skin cancer, or&#xD;
             patients with a history of cancer who completed their initial therapy &lt;1 year before&#xD;
             screening.&#xD;
&#xD;
          3. Known infectious (struvite), monogenic or other causes of stone disease for which&#xD;
             therapies are likely to significantly alter course of stone disease&#xD;
&#xD;
               1. Cystinuria&#xD;
&#xD;
               2. Primary hyperoxaluria&#xD;
&#xD;
               3. Primary xanthinuria&#xD;
&#xD;
               4. Primary hyperparathyroidism&#xD;
&#xD;
               5. Sarcoidosis&#xD;
&#xD;
               6. Medullary sponge kidney&#xD;
&#xD;
          4. History or presence of hyponatremia (serum sodium &lt;130 mmol/L) or hypo-osmolality&#xD;
             (serum osmolality &lt;275 mosm/kg)&#xD;
&#xD;
          5. Study participants with comorbidities that preclude high fluid intake or prior surgery&#xD;
             precluding high fluid intake or leading to GI fluid losses&#xD;
&#xD;
               1. History of or current Crohn's disease, ulcerative colitis, short gut syndrome&#xD;
                  (e.g. ileostomy, bowel bypass surgery to treat obesity, small bowel resection),&#xD;
                  chronic diarrhea, or GI tract ostomy.&#xD;
&#xD;
               2. History of malabsorptive (e.g., Roux-en-Y gastric bypass) or restrictive (e.g.,&#xD;
                  sleeve gastrectomy) bariatric surgery procedures&#xD;
&#xD;
               3. Congestive heart failure&#xD;
&#xD;
             i. NYHA class II or greater, and/or ii. Hospital admission in the past year for heart&#xD;
             failure d. Lung disease with a home oxygen requirement e. Chronic kidney disease (eGFR&#xD;
             &lt;30 ml/min/1.7 m2 over a 3-month period) i. For adults (age ≥18), we will use the&#xD;
             CKD-Epi equation which requires the measurement of serum creatinine only. ii. For&#xD;
             children (age &lt;18), we will use the bedside Schwartz (CKiD) formula. f. Nephrotic&#xD;
             syndrome (&gt;3.5 grams of protein per 24 hours) g. Cirrhosis with ascites&#xD;
&#xD;
          6. Women who are currently pregnant or planning pregnancy within 2 years.&#xD;
&#xD;
          7. Renal transplant recipient&#xD;
&#xD;
          8. Bedridden study participants (ECOG ≥ 3)&#xD;
&#xD;
          9. Uncorrected anatomical obstruction of the urinary tract&#xD;
&#xD;
         10. History of recurrent urinary tract infections (&gt; 3 UTI/year proven by urine culture)&#xD;
&#xD;
         11. Exclusions due to medication use:&#xD;
&#xD;
               1. Chronic use of lithium&#xD;
&#xD;
               2. Long-term glucocorticoid use (&gt; 7.5 mg prednisone daily for &gt; 30 days prior to&#xD;
                  enrollment)&#xD;
&#xD;
               3. Intake of narcotic medication on a daily basis for &gt;30 days prior to enrollment&#xD;
&#xD;
               4. Supplemental Vitamin C (&gt; 1 g daily)&#xD;
&#xD;
         12. Individuals with stones that have developed after the initiation of medications that&#xD;
             are strongly associated with USD such as carbonic anhydrase inhibitors (acetazolamide,&#xD;
             topiramate, zonisamide), high dose vitamin C (&gt; 1 g daily), high dose calcium&#xD;
             supplementation (&gt; 1,200 mg daily) AND who have discontinued or plan to discontinue&#xD;
             these medications.&#xD;
&#xD;
         13. Individuals with stones composed of medications that may crystallize in the urine&#xD;
             (guaifenesin, sulfonamides, triamterene, and the protease inhibitors indinavir and&#xD;
             nelfinavir) AND who have discontinued or plan to discontinue these medications.&#xD;
&#xD;
             Note: Individuals who are on long-term medications that increase the risk of stone&#xD;
             disease, who cannot stop these medications due to other chronic conditions (e.g., HIV)&#xD;
             and who may reduce their risk for stone recurrence through increased fluid intake,&#xD;
             will be eligible to participate in the trial. Examples of these medications include:&#xD;
&#xD;
               1. Carbonic anhydrase inhibitors (acetazolamide, topiramate, zonisamide)&#xD;
&#xD;
               2. Medications that may crystallize in the urine (guaifenesin, sulfonamides,&#xD;
                  triamterene, and the protease inhibitors indinavir and nelfinavir).&#xD;
&#xD;
         14. Study participants &lt;2 yrs life expectancy&#xD;
&#xD;
         15. Non-English Speakers&#xD;
&#xD;
         16. History of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)&#xD;
&#xD;
         17. Anatomical urologic abnormalities including ileal conduits, horseshoe kidney,&#xD;
             megaureter or solitary kidney.&#xD;
&#xD;
         18. Psychiatric conditions impairing compliance with the study&#xD;
&#xD;
         19. Vulnerable population (prisoner and/or cognitive impairment that the investigator&#xD;
             feels will impact the study participant's ability to participate in the protocol)&#xD;
&#xD;
         20. Individual who will be unable to participate in the protocol in the judgment of the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Scales, MD, MSHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Davy Andersen, MHA</last_name>
    <phone>919-668-9997</phone>
    <email>daa26@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Settles</last_name>
    <email>sharon.settles@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Waits</last_name>
      <phone>507-538-2902</phone>
      <email>waits.angela@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>John Lieske, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University, St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juanita Taylor</last_name>
      <phone>314-362-8045</phone>
      <email>PUSH@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Aleksandra Klim</last_name>
      <phone>314-747-9781</phone>
      <email>PUSH@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Henry Lai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alana Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosalie Sinanan</last_name>
      <phone>216-445-6824</phone>
      <email>sinanar@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Marina Markovic</last_name>
      <phone>1-216-444-1152</phone>
      <email>markovm@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sriharan Sivalingam, MD, MSc, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabrielle Perez</last_name>
      <phone>215-898-4897</phone>
      <email>Gabrielle.Perez@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Reese, MD, MSCE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Cuadro</last_name>
      <phone>267-234-2526</phone>
      <email>cuadrog@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Tasian, MD, MSc, MSCE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martinez Hill</last_name>
      <phone>214-456-0279</phone>
      <email>MARTINEZ.HILL@childrens.com</email>
    </contact>
    <investigator>
      <last_name>Naim Maalouf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esperanza Jackson</last_name>
      <phone>214-645-1594</phone>
      <email>esperanza.jackson@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Naim Maalouf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda Baker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Covert</last_name>
      <phone>206-616-5170</phone>
      <email>coverh@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Harper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hunter Wessells, MD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://usdrn.org/</url>
    <description>The Urinary Stone Disease Research Network (USDRN) website. The USDRN is the program conducting the PUSH study.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 2, 2017</study_first_submitted>
  <study_first_submitted_qc>August 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2017</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary Stone Disease</keyword>
  <keyword>Kidney Stone</keyword>
  <keyword>Urinary Calculi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Calculi</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Calculi</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data and samples, for subjects who consent to sharing, will be sent to the NIDDK Data and Biological Samples Repository following database lock.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>2 years after the last visit of the last participant randomized.</ipd_time_frame>
    <ipd_access_criteria>Anyone with access to the NIDDK Data and Biological Samples Repository</ipd_access_criteria>
    <ipd_url>https://repository.niddk.nih.gov/home/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

